INTRODUCTION
Cytarabine is the single most active agent available for the treatment of acute myelogenous leukemia (AML), particularly in younger patients, and contributes to the high complete remission (CR) rate in this disorder (1, 2) . Nonetheless, the majority of AML patients relapse and ultimately die of refractory disease (1) (2) (3) . As a result, there is considerable interest in identifying mechanisms that contribute to cytarabine resistance and strategies for overcoming this resistance.
A number of mechanisms of cytarabine resistance have been described, including diminished cytarabine import, increased cytarabine degradation, decreased formation or retention of cytarabine triphosphate, or reduced incorporation into DNA if the cells are not cycling. In addition, more recent reports suggest that signaling by the replication checkpoint also contributes to cytarabine resistance (4) (5) (6) (7) . This checkpoint is activated when replication inhibitors, including cytarabine (4) (5) (6) (7) (8) , cause DNA polymerases to stall but allow DNA helicases to advance, creating regions of single-stranded DNA that contribute to activation of the ATR (ataxia telangiectasia mutated and Rad3 related) kinase (9) (10) (11) . Once activated, ATR phosphorylates and activates checkpoint kinase 1 (Chk1, Fig. 1A ), which in turn phosphorylates the phosphatase Cdc25A, leading to Cdc25A degradation and cell cycle arrest (12, 13) . In addition, Chk1 stabilizes stalled replication forks, activates DNA repair, and suppresses apoptosis (12, 14) .
Consistent with these observations, previous studies have shown that Chk1 downregulation enhances the cytotoxicity of cytarabine and other nucleoside analogues (4, 6, 7, 15) . These observations provide part of the rationale for the preclinical and early clinical development of Chk1 inhibitors (14, 16, 17) . It is important to emphasize, however, that activation of the ATR/Chk1 pathway has not been previously demonstrated in clinical AML during cytarabine therapy.
Two strategies for overcoming replication checkpoint-mediated cytarabine resistance have been previously investigated. Based on the observation that Chk1 requires chaperoning by heat shock protein 90 (Hsp90) to assume an active conformation (18, 19) , cytarabine has been combined with the Hsp90 inhibitor tanespimycin. Although tanespimycin enhances the cytotoxicity of cytarabine in AML cell lines and clinical isolates in vitro (6) , the combination has proven difficult to administer in vivo because of severe toxicities (20) that likely reflect the effects of tanespimycin on multiple Hsp90 clients in normal tissues. Alternatively, cytarabine has been combined with UCN-01 in vitro and in the clinical setting (21, 22) . UCN-01 inhibits Chk1 (23, 24 ) and a number of other kinases (25) , including Chk2 and phosphoinositide-dependent kinase 1 (26, 27) , but has also been difficult to develop clinically because of toxicities in normal tissues, possibly reflecting the effect of inhibiting divers kinases. More recently described Chk1 inhibitors also inhibit Chk2 and, in some cases, cyclin-dependent kinases (28) . Because cyclindependent kinases contribute to the cell cycle progression required for lethal cytarabine incorporation into DNA (29, 30) and Chk2 contributes to apoptosis (31) , concern has been raised that these inhibitors might not be as effective at sensitizing cells to replication stress as more selective Chk1 inhibitors (32) .
SCH 900776 is a recently described inhibitor that is highly selective for Chk1 relative to Chk2 and cyclin dependent kinases (32) . Additional studies have shown that SCH 900776 enhances the cytotoxicity of hydroxyurea and gemcitabine in vitro and in vivo without increasing normal tissue toxicities (32) . To determine whether there might be a rationale for combining SCH 900776 with cytarabine in AML, the present study first assessed whether the replication checkpoint is activated during cytarabine infusion in the clinical setting and then examined the 
Leukemia samples. After informed consent was obtained under the aegis of Institutional
Review Board-approved protocols, bone marrow aspirates were acquired from two cohorts of AML patients. FAB classification and karyotype were determined in both cohorts by standard techniques (20) . Cohort 1 consisted of adult patients with relapsed or refractory acute leukemia who received therapy on a trial of sequential cytarabine and tanespimycin (20) . Bone marrow aspirates were harvested from these patients prior to therapy and again after 48 h of treatment with cytarabine, which was administered by continuous infusion at 400 mg/m 2 /day. Because this second sample was obtained prior to tanespimycin administration, the effects observed reflect the action of cytarabine alone. At the time of harvest, mononuclear cells were isolated on ficoll-Hypaque gradients, washed with ice cold serum-free RPMI 1640 medium, and immediately lysed in buffered guanidine hydrochloride under reducing conditions for SDS-PAGE (33 (vol/vol) heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin G, 100 μg/ml streptomycin, and 2 mM glutamine, and plated at 600,000 cells/plate in MethoCult® methylcellulose (StemCell Technologies, Vancouver, British Columbia) containing the indicated concentrations of cytarabine and SCH 900776. Leukemic colonies were counted after a 14-day incubation (6) . Peripheral blood mononuclear cells from normal volunteers were assayed in the same fashion except that normal erythroid and myeloid colonies were counted (34, 35) . harvested by transferring to glass filters using a Skatron semiautomatic harvester (Skatron As., Lier, Norway). The filter-bound cells were lysed with distilled water. Filter-bound radioactivity was determined by liquid scintillation counting. Aliquots containing 50 μg protein (determined by the Thermo bicinchoninic acid method) were separated by SDS-PAGE, electrophoretically transferred to nitrocellulose, and probed as described (36) .
Additional assays. Assays for apoptotic morphological changes and for the ability of AML cell lines to form colonies in 0.3% agar were performed as described (6) . Fig. 2A, lanes 7-10 vs. lane 6) , suggesting that SCH 900776 was disrupting the replication checkpoint. Consistent with this explanation, SCH 900776 also reversed the cytarabine-induced inhibition of 3 H-thymidine incorporation into DNA (Fig. 2B ). In addition, the S-phase accumulation of cells induced by a 24-h cytarabine exposure was reduced by cotreatment with 100 nM or 300 nM SCH 900776 even though SCH 900776 had no effect on cell cycle distribution when administered by itself (Fig. 2C) . SCH 900776 also increased phosphorylation of Chk1 at Ser 345 ( Fig. 2A , lanes 7-10 vs. 6), an effect that has been attributed to inhibition of PP2A-mediated dephosphorylation at that site (39) as well as increased DNA damage-induced signaling caused by incomplete replication fork stabilization, aberrant origin firing and/or override of the replication checkpoint (32) . Concomitantly, SCH 900776 also induced increased phosphorylation of H2AX, a marker of DNA damage ( Fig. 2A, lanes 7-10 vs. 
6).
We have previously shown that disruption of the replication checkpoint by gene deletion or RNA interference increases the cytotoxicity of replication stress (5) (6) (7) 15) . Consistent with these results, treatment with cytarabine and 300 nM SCH 900776 produced an increased number of U937 cells with "subdiploid" DNA content, a feature of apoptosis, compared to either agent alone (Figs. 2C, S1A and S1B). Further experiments demonstrated similar effects in several different AML cell lines, including p53-deficient HL-60 (Fig. 3A, B ) and KG1a cells (Fig. S1C) as well as p53 wildtype ML-1 cells (Fig. 3D) . Additional assays demonstrated increased numbers of cells with apoptotic morphology (K.S.F. and S.H.K., unpublished observations) and enhanced PARP1 cleavage (Fig. 3C, 
apoptosis in cells treated with cytarabine + SCH 900776 compared to cytarabine alone.
Importantly, however, SCH 900776 was unable to enhance cytarabine-induced apoptosis in K562 cells (Fig. S1D) , which are apoptosis-resistant because of Bcr/abl-mediated changes in apoptotic pathways (40) that inhibit processes downstream of DNA damage.
At the 24-h time point, the cytarabine-induced increase in ATR-mediated Chk1 Ser 317 phosphorylation also remained evident (Fig. 3C, top panel, lanes 1, 5 and 9) ; and this phosphorylation (like the phosphorylation of Chk1 Ser 345 in U937 cells) was increased further by SCH 900776 (Fig. 3C, lanes 6-8 and 10-12 ). Phosphorylation of H2AX was also increased by combining cytarabine and SCH 900776 (Fig. 3C, 4 th panel). Interestingly, the H2AX phosphorylation observed after 24 h of drug treatment, like PARP1 cleavage, was markedly diminished by addition of the caspase inhibitor (41) Q-VD-OPh (Fig. 3C, lanes 13-16 vs. 9-12 ), suggesting that some of the double strand breaks observed at late time points reflect induction of apoptosis.
SCH 900776 selectively enhances effects of cytarabine on AML cell colony formation. In view of recent results showing that Chk1 inhibition accelerates cisplatin-induced apoptosis without affecting the number of cells ultimately killed (42, 43) , we next examined the long-term impact of the cytarabine/SCH 900776 combination using colony forming assays. When U937 (Fig. 4A) or HL-60 cells (Fig. 4B) were exposed to the individual agents or the combination for 24 h, washed, and plated in soft agar, SCH 900776 had no effect on colony formation by itself but nonetheless enhanced the long-term antiproliferative effects of cytarabine in these assays, meeting the definition of synergy (44) .
To determine whether similar effects would be observed in primary clinical isolates from patients with myeloid malignancies, leukemic cells from patients in Cohort 2 ( 
exposed to cytarabine ± SCH 900776 or diluent continuously during colony formation in methylcellulose. Four patterns of response were observed (Fig. 5A-D) . In some samples, SCH 900776 had no effect by itself but nonetheless enhanced the effects of cytarabine at all concentrations (Fig. 5A) or at the higher concentrations examined (Fig. 5B) . In a few samples (Fig. 5C) , SCH 900776 not only enhanced the effects of cytarabine, but also inhibited colony formation by itself by 40-70%. In total, sensitization similar to that shown in Figs. 5A-5C was observed in 10 of 14 clinical specimens analyzed (Tables 1 and S2 ). In contrast, SCH 900776 failed to sensitize 4 of 14 specimens to cytarabine (Fig. 5D , Tables 1 and S2 ).
Based on the observation that SCH 900776 increases the antineoplastic effects of gemcitabine without enhancing myelosuppression in mice in vivo (32), we also assessed the effect of SCH 900776 on normal myeloid progenitors. In contrast to leukemic samples, progenitors from four normal volunteers exhibited little or no sensitization by SCH 900776 (Fig.   5E and 5F), raising the possibility of a therapeutic window for administering this agent with cytarabine.
In further studies, the relationship between sensitization by SCH 900776 and various features of the malignant myeloid samples was examined in a preliminary fashion. All samples were CD34 positive, reflecting their immature phenotype. As indicated in Table 1 , the presence of activating FLT3 mutations did not appear to affect sensitization by SCH 900776, although evaluation of a larger cohort is required to reach a definitive conclusion. The presence of a complex karyotype did not preclude sensitization by SCH 900776, although sensitization was observed in only 2 of 5 samples with a complex karyotype versus 7 of 9 samples without. (Table S1) , consistent with our earlier results (45) . Because previous studies have shown that Chk1 expression occurs predominantly during S phase (46) and correlates strongly with the proliferation marker PCNA in AML samples (45) , it is likely that the lack of detectable Chk1 in these samples reflected a low proliferative fraction. Among the remaining 9 pairs, we observed readily detectable Chk1 phosphorylation at baseline in 7 (Table   S1 ), consistent with observations that the ATR/Chk1 pathway is activated and contributes to survival during normal replication (10) . After 48 h of cytarabine infusion, we also observed readily detectable increases in Chk1 phosphorylation in 5 of 9 paired samples that expressed Chk1 as well as decreased Chk1 in an additional sample (Fig. 1B and Table S1 ), suggesting that the replication checkpoint is activated in at least some leukemias during cytarabine treatment in the clinical setting.
No effect of cytarabine on Chk1 phosphorylation was observed in the other three leukemias despite the presence of detectable Chk1. Because this failure to detectably activate the ATR/Chk1 pathway in response to cytarabine did not appear to correlate with FAB classification or number of prior cytarabine-containing regimens (Table S1 ), further study in a larger cohort is required to better define which AMLs activate this checkpoint during treatment and which do not. Likewise, further study is required to determine whether this checkpoint is activated during cytarabine/anthracycline combination therapy, although the observation that anthracyclines activate the ATR/Chk1/Cdc25A pathway (47, 48) 
number of nucleoside analogs, including cytarabine, in vitro (8, 22, 49) , was administered in one such attempt. Unfortunately, UCN-01 had a number of serious drawbacks in the clinic, including a long serum half-life that complicated dosing and severe toxicities when added to other chemotherapeutic agents, possibly reflecting inhibition of a large number of additional kinases (25) (26) (27) . Likewise, when cytarabine was combined with tanespimycin, which inhibits Hsp90 and thereby prevents folding of catalytically competent Chk1 (19) , the combination exhibited severe toxicities in patients with AML (20) . Importantly, however, tanespimycin induced little downregulation of Hsp90 client proteins in bone marrow blasts in situ at clinically tolerable concentrations (20) , making it impossible to assess the impact of Chk1 downregulation on cytarabine efficacy.
The third-generation Chk1 inhibitor SCH 900776 has several advantages over previous agents used to modulate the replication checkpoint. In contrast to the broad effects of UCN-01 (25), SCH 900776 exhibits selectivity for Chk1 among the ~50 kinases examined (32) . Indeed, checkpoint override assays suggest that SCH900776 is selective for Chk1 in cells at concentrations up to 30 µM (32). Moreover, unlike the checkpoint kinase inhibitor AZD7762, SCH 900776 exhibits little effect on the pro-apoptotic kinase Chk2 (32) . As is the case with any small molecule inhibitor, however, we cannot rule out the possibility that inhibition of additional kinases contributes to the observed effects of SCH 900776.
In the present study, SCH 900776 diminished cytarabine-induced replication checkpoint activation (Fig. 2) and increased cytarabine-induced apoptosis (Figs. 3 and S1 ) in AML cell lines. This enhanced killing was observed in cells with wildtype (ML-1), mutant (U937) or absent p53 (HL-60). These effects were accompanied by increased formation of phospho-Ser 139 -histone H2AX (Figs. 2A and 3C) , a commonly used marker of DNA double-strand breaks. While the increased H2AX phosphorylation observed at short time points (e.g., Fig. 2A) 
replication fork collapse that accompanies Chk1 inhibition (32), the increased H2AX phosphorylation seen at later time points paralleled caspase-mediated PARP1 cleavage and was markedly diminished by caspase inhibition (Fig. 3C) . The possibility that two distinct processes, replication fork collapse and apoptosis, can contribute to increased H2AX phosphorylation raises an important caution when considering H2AX phosphorylation for inclusion as a pharmacodynamic marker of Chk1 inhibition in future preclinical and clinical studies.
Because the typical AML sample contains only 0.5-5% of cells in S phase, a similar biochemical and cell cycle analysis of the effects of SCH 900776 on cytarabine-induced S phase progression was not feasible using clinical AML samples. Instead, further experiments utilized colony forming assays to examine the effects of the cytarabine/SCH 900776 combination. These studies demonstrated that SCH 900776 enhanced the effects of cytarabine on colony formation by human AML cell lines (Fig. 4) as well as primary AML isolates grown ex vivo (Fig. 5 , Tables 1 and S2 ). Whether this enhancement will be observed under different conditions, e.g., when leukemia cells are adherent to stroma or in xenografts, remains to be determined in future studies. Importantly, normal myeloid progenitors were affected far less by the addition of SCH 900776 (Fig. 5E ), suggesting the possibility of a therapeutic window. While these studies were in progress, Guzi et al. reported that SCH 900776 also enhances the antineoplastic effects of gemcitabine in vitro and in human tumor xenografts without appreciably altering the normal tissue toxicities of gemcitabine (32) . This selectivity for neoplastic cells, which is also seen with siRNA-mediated knockdown of Chk1, is thought to reflect redundancy in the replication checkpoint in normal cells (7, 50) . In view of these results, further studies of the SCH 900776/cytarabine combination appear warranted. 
